HC-T6IV

FILE C-T6IV·COMPANY·CURATED BY ETERNAL SEARCH

Hayflick Partners

topical rapamycin, mTOR inhibition, micro-dose delivery

modulatingsmall molecule

hayflickpartners.com·Narberth, Pennsylvania, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-T6IV

Projects

Localized micro-dose topical rapamycin for skin aging

exploratory

drug program · high

Develop localized rapamycin therapy targeting mTOR to intervene in cellular aging in skin while avoiding systemic exposure.

Topical/localized micro-dose rapamycin delivery; supported by an exploratory, prospective, randomized human skin trial measuring markers of senescence and aging.

Development-stage program positioned for FDA approval; supporting human evidence includes the 2019 exploratory randomized topical rapamycin skin-aging trial.

The supplied material states that topical rapamycin reduced markers of senescence and aging in human skin.

Localized micro-dose topical rapamycin platform

undisclosed

platform · high

Develop FDA-aligned cellular aging interventions for skin by targeting the mTOR pathway while avoiding systemic exposure.

Localized, micro-dose delivery of rapamycin as a topical therapeutic platform targeting mTOR in skin.

Hayflick Therapeutics was described as a development-stage biotechnology company advancing a first-in-class platform and was reported as named 2026 Startup of the Year at BioLabs Investor Day in Philadelphia.

A listed 2019 exploratory, prospective, randomized trial reported that topical rapamycin reduced markers of senescence and aging in human skin.

mTOR, rapamycin, and longevity research program

exploratory

research program · medium

Investigate the role of mTOR inhibition and rapamycin in aging and longevity biology.

Aging Cell research study on mTOR, rapamycin, and longevity listed among the company-associated publications.

2013 Aging Cell study listed on the Hayflick site materials.

Patent-protected localized rapamycin delivery platform

undisclosed

platform · medium

Enable measurable, localized rapamycin-based cellular aging interventions designed to avoid systemic exposure and support FDA-aligned development.

Patent-protected micro-dose delivery platform for localized topical rapamycin targeting the mTOR pathway.

Platform described publicly as patent-protected, measurable, and designed for FDA approval.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

Localized micro-dose topical rapamycin for skin aging

exploratory

drug program · high

Develop localized rapamycin therapy targeting mTOR to intervene in cellular aging in skin while avoiding systemic exposure.

Topical/localized micro-dose rapamycin delivery; supported by an exploratory, prospective, randomized human skin trial measuring markers of senescence and aging.

Development-stage program positioned for FDA approval; supporting human evidence includes the 2019 exploratory randomized topical rapamycin skin-aging trial.

The supplied material states that topical rapamycin reduced markers of senescence and aging in human skin.

Localized micro-dose topical rapamycin platform

undisclosed

platform · high

Develop FDA-aligned cellular aging interventions for skin by targeting the mTOR pathway while avoiding systemic exposure.

Localized, micro-dose delivery of rapamycin as a topical therapeutic platform targeting mTOR in skin.

A listed 2019 exploratory, prospective, randomized trial reported that topical rapamycin reduced markers of senescence and aging in human skin.

mTOR, rapamycin, and longevity research program

exploratory

research program · medium

Investigate the role of mTOR inhibition and rapamycin in aging and longevity biology.

Aging Cell research study on mTOR, rapamycin, and longevity listed among the company-associated publications.

2013 Aging Cell study listed on the Hayflick site materials.

Patent-protected localized rapamycin delivery platform

undisclosed

platform · medium

Enable measurable, localized rapamycin-based cellular aging interventions designed to avoid systemic exposure and support FDA-aligned development.

Patent-protected micro-dose delivery platform for localized topical rapamycin targeting the mTOR pathway.

Platform described publicly as patent-protected, measurable, and designed for FDA approval.